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ABSTRACT
Phosphoinositides, particularly phosphatidylinositol (3,4,5)-
trisphosphate [PI(3,4,5)P3] and phosphatidylinositol 4,5-
bisphosphate [PI(4,5)P2], are recognized by SHIP2 (also known as
INPPL1) a member of the inositol polyphosphate 5-phosphatase
family. SHIP2 dephosphorylates PI(3,4,5)P3 to form PI(3,4)P2; the
latter interacts with specific target proteins (e.g. lamellipodin).
Although the preferred SHIP2 substrate is PI(3,4,5)P3, PI(4,5)P2
can also be dephosphorylated by this enzyme to phosphatidylinositol
4-phosphate (PI4P). Through depletion of SHIP2 in the glioblastoma
cell line 1321 N1, we show that SHIP2 inhibits cell migration. In
different glioblastoma cell lines and primary cultures, SHIP2 staining
at the plasma membrane partly overlaps with PI(4,5)P2
immunoreactivity. PI(4,5)P2 was upregulated in SHIP2-deficient N1
cells as compared to control cells; in contrast, PI4P was very much
decreased in SHIP2-deficient cells. Therefore, SHIP2 controls both
PI(3,4,5)P3 and PI(4,5)P2 levels in intact cells. In 1321 N1 cells, the
PI(4,5)P2-binding protein myosin-1c was identified as a new
interactor of SHIP2. Regulation of PI(4,5)P2 and PI4P content by
SHIP2 controls 1321 N1 cell migration through the organization of
focal adhesions. Thus, our results reveal a new role of SHIP2 in the
control of PI(4,5)P2, PI4P and cell migration in PTEN-deficient
glioblastoma 1321 N1 cells.
KEY WORDS: SHIP2, Phosphoinositide, Cell migration, Focal
adhesion
INTRODUCTION
Phosphoinositides play a central role in many physiological
mechanisms allowing the recruitment of signaling proteins to
membranes through specific phosphoinositide-binding motifs
(Balla, 2013). Phosphoinositide 3-kinase (PI3K) and PTEN are
major positive and negative regulators, respectively, of the pathway,
which regulates cell growth, survival, proliferation and motility
(Chalhoub and Baker, 2009). These key signaling enzymes are two
of the most frequently mutated proteins in human cancers,
particularly in glioblastoma (Song et al., 2012). Two distinct
pathways control the dephosphorylation of phosphatidylinositol
(3,4,5)-trisphosphate [PI(3,4,5)P3]: the 3-phosphatase reaction
mediated by the tumor suppressor PTEN and several inositol
polyphosphate 5-phosphatases (Balla, 2013; Pirruccello and De
Camilli, 2012). There are ten different enzymes that often catalyze
the dephosphorylation of both phosphatidylinositol (4,5)-
bisphosphate [PI(4,5)P2] and [PI(3,4,5)P3] at the 5-position,
although it is not always clear whether or not both lipids are
modified in intact cells. Despite some sequence identity in their
catalytic sites, it appears that inositol polyphosphate 5-phosphatases
are not redundant in intact cells andmutations of several members of
this family have been found to be associated with very specific
human diseases such as the Lowe syndrome, Dent disease and
Joubert syndrome (Balla, 2013; Billcliff and Lowe, 2014;
Pirruccello and De Camilli, 2012; Staiano et al., 2015). Recent
data have clearly shown the tumor regulatory role of the inositol
polyphosphate 5-phosphatases in different type of cancers such as
glioblastoma (Kim et al., 2014). In breast cancer cells, the inositol
polyphosphate 5-phosphatase synaptojanin 2 promotes cell
migration and invasion in culture but also lung metastasis of
breast tumor xenografts in mice (Ben-Chetrit et al., 2015). In
another study, depletion of the proline-rich inositol polyphosphate
5-phosphatase PIPP (also known as INPP5J) has been shown to
increase transformation and accelerate oncogene-driven tumor
growth in vivo, whereas paradoxically reducing cell migration,
invasion and metastasis (Ooms et al., 2015); this study identifies
PIPP as a suppressor of oncogenic PI3K signaling in breast cancer.
The Src homology 2 (SH2)-domain-containing inositol
phosphatase 2 (SHIP2, also known as INPPL1) is another member
of the inositol polyphosphate 5-phosphatase family that recognizes a
series of phosphoinositides, particularly PtdIns(3,4,5)P3, as
substrate. It has been reported that SHIP2 is overexpressed in a
series of human cancers, e.g. in breast cancer cells where its
overexpression correlates with shorter survival (Prasad et al., 2008b).
In other cells, it is presented as a tumor suppressor, e.g. in squamous
cell carcinoma or glioblastoma (Elong Edimo et al., 2011; Yu et al.,
2008). SHIP2 also regulates important biological mechanisms such
as cell adhesion (Prasad et al., 2002), migration (Yu et al., 2010) or
endocytosis at the leading edge of the cells (Boucrot et al., 2015). It is
accepted that PI(3,4,5)P3 is themain SHIP2 substrate (Giuriato et al.,
2002; Nakatsu et al., 2010; Taylor et al., 2000) and its reaction
product phosphatidylinositol 3,4-bisphosphate [PI(3,4)P2] is a lipid
involved in endocytosis, lamellipodia formation (Krause and
Gautreau, 2014), invadopodium maturation (Sharma et al., 2013)
and ruffle formation (Hasegawa et al., 2011). In addition to
PI(3,4,5)P3, PI(4,5)P2 is also a substrate of SHIP2 although
evidence of this in intact cells has been more difficult to establish,
although it has been observed in a very few models, e.g. in COS-7
cells (Nakatsu et al., 2010). In COS-7 cells, SHIP2 associates at
clathrin-coated pits at the early stages of their formation. By the use of
a small interfering RNA (siRNA) approach for SHIP2, it has been
proposed that both the substrates PI(4,5)P2 and PI(3,4,5)P3 have a
positive role on coat assembly (Nakatsu et al., 2010). In other cellReceived 27 August 2015; Accepted 25 January 2016
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contexts, this is not observed; for example, in mouse embryonic
fibroblasts the amount of PI(4,5)P2 determined by [32P] labeling
was not significantly different between SHIP2+/+ and SHIP2−/−
fibroblasts (Blero et al., 2005). This was estimated in a global cell
population starting from a relatively large amount of cells (1.5×106
cells) either in unstimulated or serum stimulated cells.
Here, we specifically aimed to image the different
phosphoinositides at the plasma membrane in human
glioblastoma cell lines and primary cultures. As PTEN is one of
the most mutated genes in glioblastoma (Westhoff et al., 2014), we
have chosen to quantify the phosphoinositides in PTEN-null
glioblastoma 1321 N1 cells (hereafter N1 cells). In this model,
SHIP2-depleted cells migrate faster, concomitantly with PI(4,5)P2
upregulation and phosphatidylinositol 4-monophosphate (PI4P)
downregulation at the plasma membrane. This controls cell
migration through affecting the organization of focal adhesions.
Our results thus reveal a new role of SHIP2 in the control of
PI(4,5)P2, PI4P and cell migration in PTEN-deficient glioblastoma.
RESULTS
Lowering SHIP2 expression potentiated cell migration in N1
glioblastoma cells
We used a PTEN-deficient glioblastoma cell line (N1 cells) to
generate cell lines where SHIP2 was depleted by short hairpin RNA
(referred to as N1shSHIP2 cells) (Elong Edimo et al., 2011). These
cells show a more than 95% reduction in SHIP2 as seen by western
blotting using either antibodies against SHIP2 or against SHIP2
phosphorylated at S132 (pSHIP2 S132) (Fig. 1A). PI(3,4,5)P3 (the
Fig. 1. SHIP2-depleted N1 cells show
an increase in cell migration as
compared to vector control cells.
(A) Western blot analysis of SHIP2 and
pSHIP2 S132 expression in vector
control (N1/Vector) and N1shSHIP2
cells unstimulated or stimulated with
10% FCS. (B) Negative control of
SHIP2 on cell migration assessed by a
scratch wound assay. Phase-contrast
microscopy images were taken at 0, 2,
4, 6 h of migration. Scale bar: 75 μm.
(C) Migration distances of cells shown
after 2, 4 and 6 h of migration (mean±
s.e.m. of five determinations for each
condition in three independent
experiments). **P<0.01; ***P<0.001
(two-way ANOVA followed by
Bonferroni post-test).
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main SHIP2 substrate; Blero et al., 2001, 2005) was upregulated in
N1shSHIP2 cells as compared to vector-transfected (or control) cells,
as expected for a PI(3,4,5)P3 phosphatase (Elong Edimo et al., 2011).
This had a positive impact on the level of Akt phosphorylated at S473
and T308 (pAkt S473/T308) (Fig. S1A) and cell proliferation (Elong
Edimo et al., 2011). As SHIP2 interacts with cytoskeletal proteins
(Dyson et al., 2001), we now asked whether cell migration would also
be affected in SHIP2-depleted cells as compared to control cells. We
used a scratch wound healing assay and live-cell imaging to answer
this question. Asmeasuredwithin 6 hours ofmigration, cell migration
was significantly increased in SHIP2-deficient cells as compared to
vector-transfected cells. This could be seen both in the absence and
presence of serum (Fig. 1B,C; Movie 1). We confirmed this result
using two different human SHIP2-targeting shRNAs obtained from
the SigmaMISSION library: migration was also increased in SHIP2-
depleted cells [N1shSHIP2(1) or N1shSHIP2(2) cells as compared to
N1/Scramble, Fig. 2A–C]. Addition of the PI3K inhibitors LY-
294002 or wortmannin for 30 min completely abolished the
production of PI(3,4,5)P3 in N1 or N1shSHIP2 cells (Elong Edimo
et al., 2011). In contrast, cell migration was not influenced by the
presence of the PI3K inhibitors both in N1 vector control and
N1shSHIP2 cells. This was observed both by live-cell imaging of
individual cells, to determine the speed of migration (Fig. 2D,E) or in
a scratch wound healing assay (Fig. S2A,B). This suggests that in N1
Fig. 2. The effect of PI3K inhibitors
on cell migration in control and
SHIP2-depleted N1 cells.
(A) Western blot analysis of SHIP2
and GAPDH in total cell lysates of N1
cells expressing scrambled shRNA
(N1/Scramble) or one of two SHIP
shRNAs [N1shSHIP2(1) or
N1shSHIP2(2)] maintained in 10%
serum. (B) The respective cells were
tracked over time using chemotaxis
and migration software from Ibidi and
depicted as the ratio of axial (y-axis)
to tangential (x-axis) motility. (C) Cell
velocity over three independent
experiments is graphically depicted
as mean±s.e.m. In each experiment,
25 representative cells were followed
for each condition. *P<0.05 (Student’s
t-test for unpaired data followed by a
Mann–Whitney test). (D,E) Effect of
PI3K inhibitors. Wort, wortmannin; LY,
LY-294002. N1/Vector, vector control
cells. The data were obtained in three
independent experiments. Cell
velocity is expressed as mean±s.e.m.
P>0.05 for the cells treated with
inhibitors as compared with the
DMSO control (ns).
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cells, the mechanism of cell migration is independent of PI3K
activation.
We next aimed to determine the speed of migration in
N1shSHIP2 cells after introducing either GFP–SHIP2 (wild type)
or the GFP–SHIP2 (D607A) catalytic mutant. As shown by live-cell
imaging, cell velocity was decreased in cells expressing GFP–
SHIP2 (wild-type) by 74% as compared to cells with GFP alone.
Cells transfected with GFP–SHIP2 D607A had a small yet
significant reduction in migration; cell velocity was reduced by
20% (Fig. S2C; Movie 2). Therefore, SHIP2 negatively controls cell
migration in N1 cells by a mechanism that is not dependent on PI3K
but appears to depend on phosphoinositide phosphatase activity.We
verified that pAkt S473 was very much decreased in the presence of
the PI3K inhibitors used at the same concentrations (Fig. S1B).
Cell migration was decreased in SHIP2 depleted LN229
glioblastoma cells
We addressed the question of whether our observations in N1 cells
could be generalized to other glioblastoma cell lines. For this, we
chose the PTEN-containing cell line LN229 and the same lentiviral
constructs previously used to infect N1 cells to generate
LN229shSHIP2(1) and LN229shSHIP2(2) cells. Western blot
analysis shows that SHIP2 expression was reduced by ∼60% in
the two SHIP2-depleted cells as compared to LN229 with scramble
shRNA Fig. 3A. Cell migration was significantly reduced in the
SHIP2-depleted cells (Fig. 3B,C). Interestingly, LY-294002
inhibited cell velocity both in the LN229 control and SHIP2-
depleted cells (Fig. 3C). Therefore, the SHIP2-mediated negative
control of cell migration in N1 cells cannot be generalized to other
glioblastoma cell lines (i.e. LN229 cells).
SHIP2 staining at the plasma membrane partially overlaps
with PI(4,5)P2 immunoreactivity in glioblastoma
In order to explain our observations in N1 cells, we first
characterized the intracellular localization of SHIP2 in relation to
its substrates. Data reported by Hammond et al. have established
conditions that allow PI(4,5)P2 immunostaining at the plasma
membrane (Hammond et al., 2009). These conditions involve the
absence of ‘Triton X-100’ to permeabilize the cells and the use of
‘saponin’ (as outlined in the Materials and Methods section) to stain
PI(4,5)P2. We thus addressed the question of the intracellular
localization of SHIP2 using the conditions described in Hammond
et al. FixedN1 cells were stained for PI(4,5)P2, PI(3,4,5)P3 and total
SHIP2 (Fig. 4A).We found that a large proportion of the total SHIP2
was at the plasma membrane and partly colocalized with PI(4,5)P2.
This result very much depended on the immunostaining being
performed in the absence of Triton X-100 (data not shown). This
result could be generalized to two distinct glioblastoma cell lines (U-
87 MG and LN229) and, importantly, to three primary cultures of
human glioblastoma (Fig. 4B; Fig. S3A). The same result was
observed despite variable amounts of SHIP2 being present at the
plasma membrane in different primary cultures. Western blot
analysis confirmed the expression of SHIP2, pSHIP2 S132 and
PTEN in primary cells (two primary cell cultures of glioblastoma are
shown in Fig. S3B). We conclude that in glioblastoma cell lines and
primary cultures, SHIP2 can be localized at the plasma membrane
where, at least partially, it overlaps with PI(4,5)P2.
SHIP2 controls both PI(4,5)P2 and PI4P at the plasma
membrane of N1 cells
As PI3K inhibitors failed to inhibit migration of N1 cells, we
hypothesized that PI(4,5)P2 might be the relevant SHIP2 substrate
to explain our data. SHIP2 depletion would change the relative
content of PI(4,5)P2 and PI4P at the plasma membrane provided
PI(4,5)P2 is a genuine cellular SHIP2 substrate. A representative
staining of PI(4,5)P2 in N1 vector control and N1shSHIP2 is shown
in Fig. 4C. In the same cells, SHIP2 immunoreactivity in
N1shSHIP2 cells is reduced by 90% compared to its control value
Fig. 3. Migration of SHIP2-depleted LN229 cells. (A)Western blot analysis of
SHIP2 and GAPDH in total cell lysates of LN229 cells expressing scrambled
shRNA (LN229/Scramble) or one of two SHIP shRNAs [LN229shSHIP2(1) or
LN229shSHIP2(2)] maintained in 10% serum. (B,C) Migration was followed
and analyzed as described in Fig. 2B,C, *P<0.05; **P<0.005; ****P<0.0001
(Student’s t-test for unpaired data followed by a Mann–Whitney test).
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Fig. 4. SHIP2 and PI(4,5)P2 localization at the plasmamembrane in glioblastoma cell lines. (A) Immunostaining of PI(4,5)P2, PI(3,4,5)P3 and SHIP2 in N1
cells. GFP–PH-Btk-transfected N1 cells plated on coverslips were fixed and stained with anti-PI(4,5)P2, anti-SHIP2 and anti-GFP antibodies. (B) Immunostaining
of endogenous PI(4,5)P2 and SHIP2 in human glioblastoma cell lines. Nuclei were stained with Hoechst 33342 in blue. Images were obtained by confocal
microscopy. (C) Immunostaining of endogenous PI(4,5)P2 in N1 vector control (N1/Vector) and N1shSHIP2 cells. The PI(4,5)P2 plasma membrane signal was
quantified at 20× as the mean of the fluorescence intensity. Each point represents a measurement of a single field of cells. Bars represent mean fluorescence of
several fields. ***P<0.0001 (Student’s t-test for unpaired data followed by a Mann–Whitney test). (D) Immunostaining of endogenous SHIP2 in N1/Vector and
N1shSHIP2 cells. Cells were visualized using Zeiss LSM780with a 20× objective (NA 0.8). Nuclei were stainedwith Hoechst 33342 in blue. The SHIP2 signal was
quantified as themean of fluorescence intensity. Data aremean±s.e.m. (2000 cells). TheSHIP2 signal was quantified as themean of the fluorescence intensity as
in C. Bars represent mean fluorescence intensity of several fields (in total of 2000 cells). ***P<0.0001 (Student’s t-test followed by Mann–Whitney test). Scale
bars: 5 µm (A,B); 50 µm (C,D).
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(Fig. 4D). PI(4,5)P2 was indeed increased by twofold in
N1shSHIP2 cells compared to control or vector-transfected cells
(Fig. 4C). In contrast, membranous PI4P was decreased by 60% in
SHIP2-deficient cells as compared to SHIP2-containing N1 vector
control cells (Fig. 5A). Transfection experiments where we
reintroduced X-press-tagged wild-type or phosphatase-dead
SHIP2 in N1shSHIP2 cells showed that PI(4,5)P2 was decreased
in wild-type SHIP2-transfected cells as compared to in cells with
phosphatase-dead SHIP2 D607A (Fig. 5B). This was inverted when
PI4P was quantified: PI4P was increased in wild-type SHIP2-
transfected cells as compared to the mutated SHIP2 (Fig. 5C). Thus,
the observed changes in the PI(4,5)P2-to-PI4P ratio at the plasma
membrane in SHIP2-depleted N1 cells are dependent on depletion
of SHIP2 catalytic activity.
The use of protein domains for the detection of phosphoinositides
as biosensors has been reported in previous studies (Davies et al.,
2014; Ooms et al., 2015). Fluorescence intensity has been determined
in N1 vector control cells or N1shSHIP2 cells transfected with GFP–
PH-PLCδ1, used as a probe for PI(4,5)P2 (Stauffer et al., 1998). We
have taken into account all cells that were positive for GFP (i.e.
transfected by the probe). We observed a 2.3-fold increase in
fluorescence intensity in N1shSHIP2 as compared to N1 vector
control cells (Fig. 6A) in agreement with the PI(4,5)P2 antibody data.
We also used GFP–PH-TAPP1 to monitor the content of PI(3,4)P2.
The staining of this biosensor was abundant in lamellipodia but
decreased in N1shSHIP2 cells compared to control (Fig. 5D).
Given that our data suggested an important role of PI(4,5)P2 is the
control of cell migration in N1shSHIP2 cells, we asked whether
migration would be affected when blocking PI(3,4,5)P3 or
PI(4,5)P2 by overexpression of a specific probe for each lipid. We
therefore transfected GFP–PH-Btk [a biosensor of PI(3,4,5)P3] and
GFP–PH-PLCδ1 in N1 shSHIP2 cells. Live cell imaging shows that
GFP–PH-Btk decreases cell migration by reducing cell velocity by
17% whereas GFP–PH-PLCδ1 reduces velocity by 65% (Fig. 6B;
Movie 3). The data suggest that PI(4,5)P2 plays a major role in the
control of cell migration. We also determined in vivo protrusion
dynamics in N1 vector control and N1shSHIP2 cells by bright-field
dynamics: SHIP2-depleted cells showed significantly more
protrusions as compared to N1 vector control cells (Fig. S3C,D).
Finally, we estimated the levels of PI(4,5)P2 and PI4P after labeling
the cells with 32P. The ratio of PI(4,5)P2 to PI4P was significantly
increased in N1shSHIP2 cells as compared to N1 vector control
(Fig. S3E).
We conclude that in N1 cells, SHIP2 controls the balance
between PI(4,5)P2 and PI4P at the plasma membrane consistent
with its previously established catalytic activity towards PI(4,5)P2
in vitro (Giuriato et al., 2002; Nakatsu et al., 2010; Taylor et al.,
2000; Vandeput et al., 2007). In addition, it is involved in
controlling the PI(3,4,5)P3–PI(3,4)P2 balance in lamellipodia.
Quantification of pFAK Y397, paxillin and vinculin staining in
N1 deficient cells
PI(4,5)P2 has several downstream cellular effectors. It activates
focal adhesion kinase (FAK, also known as PTK2) by a
combination of clustering and conformational changes that
promote efficient autophosphorylation (Goni et al., 2014).
Consistent with SHIP2-mediated control of PI(4,5)P2 levels,
western blotting showed that FAK phosphorylated at Y397
(pFAK Y397) was upregulated in N1shSHIP2 cells as compared
to control cells, with no change in the total levels of FAK (Fig. 7A).
Focal adhesion length was quantified by determining the length of
pFAK Y397 staining in N1 control and N1 SHIP2-deficient cells
(Fig. 7B). This was based on the report that the mean length of focal
adhesions precisely predicts cell speed and migration (Kim and
Wirtz, 2013). The quantification was made in the absence and
presence of fetal calf serum (FCS) for 30, 60 and 120 min. The focal
adhesion length was increased in N1shSHIP2 cells as compared to
control cells at any time of FCS stimulation and even in the absence
of any stimulation (Fig. 7B, right panel). Similar results were
obtained using two other focal adhesion proteins, paxillin and
vinculin (Fig. 7C,D), with a clear impact on F-actin staining
(Fig. 7E). We conclude that, besides upregulation of pFAK Y397,
focal adhesion length is specifically increased in SHIP2-deficient
cells, suggestive for focal adhesion turnover controlled by SHIP2.
SHIP2 interaction with myosin-1c and filamin A in N1 cells
SHIP2-interacting proteins are often cytoskeletal and focal adhesion
proteins (reviewed in Elong Edimo et al., 2013). SHIP2 is part of the
integrin adhesome network (Wolfenson et al., 2013) and localizes to
circular dorsal ruffles (Hasegawa et al., 2011), which are important
structures implicated in the initiation of cell migration. We asked
whether SHIP2 localization in N1 cells also involves focal adhesion
proteins and/or PI(4,5)P2-binding proteins. Potential SHIP2-
binding proteins co-immunoprecipitating with SHIP2 were
subjected to mass spectrometry analysis. Preimmune serum was
used as a negative control (Fig. S4A). A staining of SHIP2
immunoprecipitated proteins allowed the identification of known
SHIP2 interactors based on published data in other cell types [e.g.
Dok1 and intersectin (Cunningham et al., 2010; Nakatsu et al.,
2010; Xie et al., 2008)]. In addition, the actin-binding and
PI(4,5)P2-binding protein myosin-1c (Myo1c) was identified as
a new potential interactor with a Mascot score of 857. The
interaction between SHIP2 and Myo1c was confirmed by
co-immunoprecipitation in N1 cells at endogenous level (Fig.
S4B,C). The previously identified SHIP2 interactor and actin-
binding protein filamin A [in COS-7 cells (Dyson et al., 2001)] was
also present in the SHIP2 immunoprecipitate (Fig. S4C).
Conversely, SHIP2 and Myo1c were present when filamin A was
immunoprecipitated and the blot probed with anti-SHIP2 and
anti-Myo1c antibodies (Fig. S4D).
DISCUSSION
In this study, we provide evidence of a negative control of SHIP2 in
cell migration in PTEN-null glioblastoma 1321 N1 cells. This was
shown in cells depleted of SHIP2 by the use of three different
shRNAs. The migration defect could be rescued in N1shSHIP2 cells
by introducing GFP–SHIP2 but not its catalytic mutant. Therefore,
the mechanism controlling migration involves SHIP2 phosphatase
activity, which modulates of the balance between PI(4,5)P2 and
PI4P and changes in focal adhesion dynamics. In N1 cells, cell
migration was not inhibited by the two PI3K inhibitors we have
tested. However, PI3K inhibitors do inhibit cell migration in a
different glioblastoma cell line LN229 cells. In LN229 cells,
depletion of SHIP2 inhibited cell migration. Hence, the negative
control of SHIP2 on cell migration in N1 cells is dependent on the
cell type and varies between different glioblastoma cells.
We show for the first time SHIP2 immunostaining at the plasma
membrane in very distinct glioblastoma cell lines and human
primary cultures. SHIP2 immunoreactivity partly overlaps with the
staining of PI(4,5)P2. Overall these findings were unexpected as
SHIP2 was essentially reported to be perinuclear and to translocate
at the plasma membrane in the presence of growth factors or insulin
(Ishihara et al., 2002; Onnockx et al., 2008; Pesesse et al., 2001;
Takabayashi et al., 2010; Wang et al., 2004). We have shown in this
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Fig. 5. See next page for legend.
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study that the conditions that preserve plasma membrane staining
for PI(4,5)P2 (Hammond et al., 2009) also apply to staining of
SHIP2. It will be interesting to use the same conditions to stain and
compare other members of the phosphoinositide 5-phosphatase
family.
SHIP2 immunoreactivity partially overlaps with PI(4,5)P2
immunoreactivity in N1 cells and other glioblastoma cell lines
and primary cultures, arguing that the lipid phosphatase might
perhaps control PI(4,5)P2 in several glioblastoma cell types. We
have reported that PI(4,5)P2 in the nucleus was elevated in
N1shSHIP2 cells as compared to control cells (Elong Edimo
et al., 2011). We have now quantified PI(4,5)P2 at the plasma
membrane of the same cells both by the use of antibodies and a
PI(4,5)P2 biosensor (Stauffer et al., 1998). The conclusion is similar
for both techniques: PI(4,5)P2 at the plasma membrane is elevated
in N1shSHIP2 cells compared to control. To further support a
role of PI(4,5)P2, we overexpressed a specific probe for either
PI(3,4,5)P3 or PI(4,5)P2 to see whether migration was affected in
N1shSHIP2 cells. We observe a minor decrease in migration in cells
expressing GFP–PH-Btk, a biosensor for PI(3,4,5)P3 but in contrast
a major effect on migration in cells expressing GFP–PH-PLCδ1, a
biosensor for PI(4,5)P2 in N1shSHIP2 cells. PI(4,5)P2 therefore
plays a major role in the control of cell migration in this cell line.
Finally, data reported by the group of Anderson shows that type I γ
phosphatidylinositol 4-phosphate 5-kinase (PIPKIγ) knockdown
cells have fewer protrusions as compared to control cells (Choi
et al., 2013) and that serum-induced migration was significantly
attenuated by PIPKIγ knockdown. This indicates that migration and
lamellipodium formation require PIPKIγ and PI(4,5)P2 (Choi et al.,
2013). We quantified the protrusions by live-cell imaging in SHIP2-
depleted N1 cells as compared to N1 vector control cells, and we see
more protrusions in N1shSHIP2 as compared to N1 vector control
cells. This result is consistent with an increase in PI(4,5)P2 in
N1shSHIP2 cells compared to control.
Previous data from the De Camilli laboratory has shown that in
COS-7 cells, SHIP2 was concentrated at endocytic clathrin-coated pits
during early stages of their maturation (Nakatsu et al., 2010). The
possibility was presented that SHIP2 might cause PI(4,5)P2 to decline.
It, however, remained unclear whether altered clathrin-coated pit
dynamics is a consequence of change in the levels of PI(3,4,5)P3,
PI(4,5)P2 or both (Posor et al., 2015). Based on our data, we suggest
that SHIP2 metabolizes both substrates PI(3,4,5)P3 and PI(4,5)P2: in
our model of glioblastoma (N1 cells), PI(3,4,5)P3 modulation has an
impact on cell proliferation, whereas PI(4,5)P2 modulation is a key
factor in the control of cell migration. Interestingly, PIPKIγ, which
produces PI(4,5)P2, targets and regulates focal adhesions (Ling et al.,
2002). The PI(4,5)P2-generating enzyme interacts with the cytoskeletal
regulator IQGAP1 and functions together in the regulation of
directional cell migration (Choi et al., 2013). Overall, it thus appears
that PI(4,5)P2 levels can be controlled by multiple mechanisms both
for its production and for its dephosphorylation by SHIP2.
SHIP2 is part of the adhesome and can interact with a large
number of cytoskeletal and focal adhesion proteins, and particularly
with filamin A (Dyson et al., 2001), vinexin (Paternotte et al., 2005),
intersectin (Nakatsu et al., 2010; Xie et al., 2008), RhoA (Kato et al.,
2012) and, as shown here in N1 cells, Myo1c. Using the same
SHIP2 immunoprecipitation and washing conditions used in N1
cells, we could not show the presence of Myo1c in SHIP2
immunoprecipitates from COS-7 lysates (data not shown). This
suggests that the presence of the SHIP2–Myo1c complex might be
rather specific for N1 cells. Interestingly, in a different cell type,
nephrin regulates lamellipodia formation by assembling a protein
complex that includes SHIP2, filamin and lamellipodin
(Venkatareddy et al., 2011). SHIP2 is part of the adhesome, and it
has been proposed that, on average, each adhesome protein has
approximately nine different potential partners (Zaidel-Bar and
Geiger, 2010). This is in agreement with our data and suggests that a
complex of cytoskeletal proteins, as identified in N1 cells, is
constantly interacting with SHIP2. We have shown that N1shSHIP2
cells transfected with a SHIP2 catalytic mutant, GFP–SHIP2
D607A, had a small yet significant reduction in migration (i.e. 20%)
as compared to cells transfected with GFP alone. This suggests that
docking properties of SHIP2 might also influence cell migration.
We speculate that this contributes to the specificity of SHIP2 acting
through both its phosphatase activity and intrinsic docking
properties (Erneux et al., 2011).
Reports in the literature reveal that the function of SHIP2 as a
pro- or anti-oncogene is not clear and very much depends on the
cellular model (Elong Edimo et al., 2011; Prasad et al., 2008a;
Taylor et al., 2000). In breast cancer cells, where it has been mostly
studied, SHIP2 participates in the mechanism of invadopodium
maturation by producing the key lipid PI(3,4)P2 (Sharma et al.,
2013). As PI(3,4,5)P3 is considered as the major SHIP2 substrate
(Balla, 2013; Vandeput et al., 2007), the PI3K–Akt pathway is
often upregulated in SHIP2-depleted cells as compared to control
cells. This was the case in SHIP2-depleted N1 cells compared to
control cells (Elong Edimo et al., 2011). Therefore, SHIP2 can be
considered as a tumor suppressor in some cells; for example, in
keratinocytes (Yu et al., 2008) and in PTEN-deficient glioblastoma
(Elong Edimo et al., 2011; Taylor et al., 2000). Cell migration is a
fundamental mechanism in physiology but also in many diseases
such as cancer (Sun et al., 2013). Here, as well, as also reported in
other studies, the influence of SHIP2 on cell migration varies from
one cell type to the other. For example, silencing SHIP2 in
HEK293 cells increases cell migration, but in U251 glioma cells
depletion of SHIP2 attenuates cell polarization and migration (Kato
Fig. 5. SHIP2 transfection in N1shSHIP2 cells affects plasmamembrane PI
(4,5)P2 and PI4P levels. (A) Immunostaining of PI4P in N1 vector control (N1/
Vector) and N1shSHIP2 cells. After 5 min of stimulation with 10% FCS, cells
were fixed and stained for PI4P and SHIP2. The PI4P plasmamembrane signal
was quantified. Each point represents a measurement of a single cell; bars
represent normalized mean fluorescence (50 cells). ***P<0.0001 (Student’s
t-test followed by Mann–Whitney test). (B) N1shSHIP2 cells transfected with
X-press-tagged wild-type SHIP2 (wt) or X-press-tagged SHIP2 D607A (D/A,
catalytic mutant) cells were plated on coverslips and cultured in the presence of
10% FCS for 24 h before starvation. After 5 min of stimulation with 10% FCS,
cells were fixed and stained with PI(4,5)P2 and Xpress. The PI(4,5)P2 plasma
membrane signal was quantified. Each point represents a measurement of the
PI(4,5)P2 to Xpress ratio from a single cell. Bars represent normalized mean
fluorescence. ***P<0.0001 (Student’s t-test followed by Mann–Whitney test).
(C) N1shSHIP2 cells transfected with X-press-tagged wild-type SHIP2 or
X-press-tagged SHIP2 D607A (catalytic mutant) cells were plated on
coverslips and cultured in the presence of 10% FCS for 24 h before starvation.
After 5 min of stimulation with 10% FCS, cells were fixed and stained with PI4P
and Xpress. The PI4P plasma membrane signal was quantified. Each point
represents a measurement of the PI4P to Xpress ratio from a single cell. Bars
represent normalized mean fluorescence. ***P<0.0001 (Student’s t-test
followed by Mann–Whitney test). (D) N1shSHIP2 cells transfected with GFP–
PH-TAPP1 to probe PI(3,4)P2 were plated on coverslips and cultured in the
presence of 10% FCS for 24 h before starvation. After 5 min of stimulation with
10% FCS, cells were fixed and stained for GFP. The PI(3,4)P2 signal was
quantified. Each point represents a measurement of PI(3,4)P2 after
normalization from a single cell. Bars represent normalized mean
fluorescence. ***P<0.0001 (Student’s t-test followed by Mann–Whitney test).
In B–D, nuclei were stained with Hoechst 33342 in blue, and cells were
visualized using Zeiss LSM780 and a 63× oil objective (NA 1.46). Scale
bars: 5 µm.
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et al., 2012; Yu et al., 2010). Kato et al. interpreted their data by
showing an association between SHIP2 and RhoA and observed an
impairment of proper PI(3,4,5)P3 localization in SHIP2-depleted
U251 cells (Kato et al., 2012). In this model, PI(3,4,5)P3 at the
leading edge was very much decreased both in SHIP2-depleted
cells as compared to control cells and in the presence of the PI3K
inhibitor LY-294002. The levels of PI(4,5)P2 at the plasma
membrane were not reported in this study. We suggest an
alternative explanation based on the ability of SHIP2 to
recognize PI(4,5)P2 as substrate, in addition to PI(3,4,5)P3
(Fig. 8). It will be interesting to establish whether this last
mechanism can apply in U251 cells.
The importance of PI(3,4)P2 interaction with lamellipodin and its
function in migration and endocytosis has been reported (Krause and
Gautreau, 2014). In ourmodel of N1 cells,we have seen that PI(3,4)P2
is actually decreased in SHIP2-depletedN1shSHIP2 cells as compared
to N1 vector control cells. Neither PI3K inhibitors nor Akt inhibitors
(Akti; W.E.E., unpublished data) influence cell migration in N1 vector
control or N1shSHIP2 cells. This suggests that migration is not
controlled by a PI(3,4,5)P3–PI(3,4)P2 pathway in our model cell line
(Fig. 8). Other phosphoinositides, in particular PI(4,5)P2, have been
reported to modulate cytoskeletal organization and cell migration
(Choi et al., 2015; Sun et al., 2013; Tsujita and Itoh, 2015). PI(4,5)P2
binding of IQGAP1 is important for cell morphology and migration,
Fig. 6. Inhibition of cell migration
visualized using the biosensor GFP–
PH-PLCδ in N1shSHIP2 cells. (A) N1
vector control (N1/Vector) and
N1shSHIP2 cell lines were plated on
3-cm tissue culture dish and transfected
with GFP–PH-PLCδ for 24 h. Cells were
plated on coverslips. Representative
images of GFP immunostaining are
shown. Scale bar: 50 μm. Each point
represents a measurement of a single
cell; bars represent mean fluorescence.
GFP–PH-PLCδ fluorescence
intensities. 100 cells for each cell line
were analyzed and scored for three
independent transfections.
***P<0.0001 compared with vector
control cells (Student’s t-test for
unpaired data followed by Mann–
Whitney test). (B) Individual cell
migration of N1shSHIP2 cells
transfected with GFP, GFP–PH-PLCδ
and GFP–PH-Btk tracked over time and
depicted as the ratio of axial (y-axis) to
tangential (x-axis) motility. The data
depicts a minimum of eight
representative cells in three
independent experiments. Cell velocity
is graphically depicted as mean±s.e.m.
***P<0.0001 compared with control
(Student’s t-test for unpaired data as in
Fig. 2).
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Fig. 7. SHIP2 controls focal adhesion dynamics in N1 cells. (A) SHIP2, pFAK Y397, and total FAK expression were determined in cell lysates from N1 vector
control (N1/Vector) and N1shSHIP2 cells unstimulated or stimulated with 10% FCS. (B) SHIP2 controls the focal adhesion dynamics. N1/Vector and N1shSHIP2
were serum starved (left panel) and stained for pFAK Y397. Nuclei were stained with Hoechst 33342 in blue. Cells were visualized using a Zeiss LSM780 63× oil
objective (NA 1.46). Scale bars: 50 µm (main image), 5 µm (inset). The right panel shows a quantification of the focal adhesion length of starved cells and
stimulated with 10%FCS for 30, 60 and 120 min at 37°C. Focal adhesion length wasmeasured in 60 cells in three independent experiments and expressed as the
mean±s.e.m. **P<0.01; ***P<0.001 (two-way ANOVA followed by Bonferroni post-test). (C) Immunocytochemistry of pFAK Y397 and Paxillin in N1/vector and
N1shSHIP2 cells. (D) Immunocytochemistry of pFAK Y397 and Vinculin in N1/vector and N1shSHIP2 cells. (E) Immunostaining of F-actin in N1/vector and
N1shSHIP2 cells. In C–E, cells were unstimulated or stimulated with 10% of FCS for 5 min. Nuclei were stained with Hoechst 33342 in blue, and cells were
visualized using a Zeiss LSM780, 63× oil objective (NA 1.46). Scale bars: 5 µm.
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and lamellipodium formation also requires PIPKIγ (Choi et al., 2013).
Our data suggest that, in N1 cells, SHIP2 controls PI(4,5)P2 levels,
which could control focal adhesions and/or possibly IQGAP1 activity.
PI(4,5)P2 is an upstream activator of pFAK Y397 in focal adhesions
and has been reported to change cell attachment and spreading (Goni
et al., 2014). We observed that pFAK Y397 is actually upregulated in
SHIP2-deficient cells as compared to control cells. This has a positive
impact on focal adhesion length (pFAK Y397 immunoreactivity) and
cell migration (Fig. 8).
We have evidence that in PTEN-positive LN229 cells, migration
is decreased in SHIP2-depleted cells. The reason for this is not yet
understood; we speculate that the content of the different
phosphoinositides PI(4,5)P2, PI(3,4)P2 and PI(3,4,5)P3 could be
very different between cell types. Our data in primary glioblastoma
show that PI(4,5)P2 levels, as assessed by immunostaining, are very
different between different primary cell cultures. In support of this,
SHIP2 and PTEN levels determined by western blotting are quite
different in different primary human glioblastoma cells from
different patients (W.E.E., unpublished data). SHIP2 could be
highly expressed, expressed at low levels or even absent, and the
same applies for PTEN. In glioblastoma, intratumor heterogeneity
of PTEN expression is well known and reflects cancer evolutionary
dynamics (Sottoriva et al., 2013). It is likely that the same concept
would apply for SHIP2 and other members of the inositol
polyphosphate 5-phosphatase family [e.g. INPP5K (Davies et al.,
2014)]. It would be interesting to establish whether loss of PTEN
correlates with a role for SHIP2 in migration in different primary
cultures of human glioblastoma with different genotypes.
MATERIALS AND METHODS
Reagents
Anti-SHIP2monoclonal antibody used for total SHIP2 immunostaining was
from Novus (Cambridge, UK; catalog number H00003636-M01). It was
initially characterized in Deneubourg et al., 2014; McNulty et al., 2011 and
used at 1:300. Anti-SHIP2 antibodies used in immunoprecipitation have
been characterized previously (Muraille et al., 1999). Anti-SHIP2 antibody
phosphorylated on S132 was custom-made in the laboratory (Elong Edimo
et al., 2011). The monoclonal antibody against the filamin A N-terminal
(5–40 amino acids) (catalog number sc-17749) was from Santa Cruz
Biotechnology (Heidelberg, Germany) and was used at 1:500 dilution.
Myo1c polyclonal antibody (catalog number M3567, used at 1:1000),
vinculin antibody (catalog number V4505, used at 1:300), Erk inhibitor U0-
126 (catalog number U120), LY294002 hydrochloride (catalog number
L9908) and wortmannin (catalog number W-1628) were from Sigma-
Aldrich (Diegem, Belgium). Polyclonal pFAK Y397 and total FAK
antibodies (catalog number 3283 and 3285) were from Cell Signaling
Technology (Bioke, The Netherlands; used at 1:350 and 1:100,
respectively). Antibodies against pAkt S473 (catalog number, 9271 L),
pAkt T308 (catalog number, 9275L) and total Akt (catalog number, 9272S)
were from Cell Signaling Technology and used at 1:500. Paxillin antibody
5H11 (catalog number 3127) was from Abcam (Cambridge, UK used at
1:300). Antibodies to PI(4,5)P2 (2C11) (catalog number sc-53412, used at
1:200) and PI4P (catalog number s-P004, used at 1:50) were fromSanta Cruz
Biotechnology and Echelon (Le-Perray-en-Yvelines, France), respectively.
Myo1c shRNA plasmid (h) (catalog number sc-44604-SH) was from Santa
Cruz Biotechnology. Protein A Sepharose™ CL-4B was from GE
Healthcare Bio-Sciences (Diegem, Belgium). Lipofectamine™ (catalog
number 11668-019), Alexa-Fluor-594-conjugated phalloidin (catalog
number A12381), Alexa-Fluor-488-conjugated donkey (catalog number
A21206) and Alexa-Fluor-594-conjugated goat (catalog number A11012)
anti-rabbit-IgG, Alexa-Fluor-488-conjugated donkey (catalog number
A21202) and Alexa-Fluor-594-conjugated goat (catalog number A11032)
anti-mouse-IgG, Hoechst 33342 (catalog number H-3570) and normal
goat serum (reference 16210-064) were from Invitrogen (Breda, The
Netherlands). The Glycergel mounting medium (catalog number C0563)
was from Dako (Heverlee, Belgium). mRFP or GFP-tagged PH-PLCδ1,
GFP–PH-Btk, GFP–PH-TAPP1were provided byTamasBalla (NIH,USA).
The X-press-tagged SHIP2 wild-type and catalytic mutants are as reported
previously (Pesesse et al., 2001). GFP–SHIP2 was kindly provided by Chris
Mitchell (Monash University, Australia). The GFP–SHIP2 catalytic mutant
(D607A) was supplied by MRC-PPU reagents at University of Dundee. We
Fig. 8. A model depicting two control mechanisms by which phosphoinositides modulate cell migration. In PTEN-null 1321 N1 cells, SHIP2 could act on
two substrates PI(3,4,5)P3 and PI(4,5)P2. Migration was not affected in the presence of PI3K inhibitors. PI(4,5)P2 is upregulated in SHIP2-depleted cells, thereby
controlling focal adhesion (FA) dynamics and cell migration.
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verified that both X-press-tagged SHIP2 and GFP–SHIP2 are active in a
phosphatase assay using either PI(3,4,5)P2 or PI(4,5)P2 as substrate
(Vandeput et al., 2006).
Cell culture
Human glioblastoma cell lines (1321 N1, LN-229 and T-98G cells) and U-
87MG cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (GIBCO, CA), supplemented with 5% fetal calf serum (FCS),
2% penicillin-streptomycin and maintained at 37°C, 5% CO2. Cells were
kindly provided by Isabelle Salmon (Hôpital Erasme, Université Libre de
Bruxelles) and Peter Downes (University of Dundee, UK), and have been
characterized previously (Elong Edimo et al., 2011, 2013). Cells were
regularly checked to be free of mycoplasma. Human glioblastoma
specimens were obtained within the framework of a study that received
approval from the ethical review board of the University Hospital of Utrecht,
The Netherlands, according to the principles of the Declaration of Helsinki.
Written informed consent was obtained from the patients prior to surgery.
Primary cultures of human glioblastoma were prepared as previously
reported (Robe et al., 2004) and maintained anonymously in culture
facilities at the laboratory of HumanGenetics, University of Lieg̀e, Belgium.
Generation of stable shRNA-expressing cells
N1 cells were plated at 1×105 cells per well in 12-well plates, 1 day before
transfection. Cells were transiently transfected with the desired pSUPER
constructs using Lipofectamine™ 2000 (Elong Edimo et al., 2011). After
recovery, the cells were selected by incubation for 3 days with 6 μg/ml
puromycin. Cells resistant to puromycin were counted, diluted and distributed
in 96-well plates so that one cell perwell was achieved.Clonal populationswere
then expanded and analyzed for SHIP2 and Myo1c expression. N1shSHIP2
cells devoid of SHIP2 expression (as analyzed by western blotting) were
generated by increasing the puromycin concentration up to 3 µg/ml.
Generation of stable SHIP2 depleted N1 and LN229 glioblastoma
cells by lentiviral infection
N1 and LN229 cells were transduced with Sigma MISSION lentiviral
transduction particles containing a pLK0.1-Puro plasmid encoding either a
non-mammalian shRNA (Scramble SHC02) or one of two SHIP2-specific
targeting shRNAs [reference number TRCN 0000052810 and TRCN
0000052808 for sh(1) and sh(2), respectively] at a multiplicity of infection
of 2.8 in growth medium supplemented with 8 µg/ml of polybrene overnight
at 37°C. Transduced cells were selected in growth medium supplemented
with 6 µg/ml puromycin for 3 weeks then subsequently maintained in
growth medium without puromycin.
Scratch assay for migration and live-cell imaging
Culture-inserts for self-insertion were obtained from Proxylab and used to
generate a scratch. N1 vector control or N1shSHIP2 cells were allowed to
migrate for 6–8 h. The migration distance was quantified by ImageJ.
Individual cells plated on FluoroDish™ (μ-Dish 35 mm, high, glass bottom
from Ibidi) were allowed to migrate and analyzed with a Leica DM6000B
microscope for live-cell imaging.
Cell transfection of GFP constructs
N1 vector control or shSHIP2 cells were kept in 5% FCS with no antibiotics
for 24 h and were transfected at 90% confluence. For 9-cm diameter cell
dishes, 60 µl of Lipofectamine™ 2000 and 24 µg DNAwere used according
to manufacturer’s protocol and cells were allowed to express the constructs
for 48 h before lysis.
Proteins extract preparation and immunoprecipitation
N1 cells were lysed in buffer A (10 mM Tris-HCl pH 7.5, 150 mM KCl,
12 mM 2-mercaptoethanol, 100 mM NaF, 0.5% NP-40, 0.01 μM sodium
vanadate and 2 mM EDTA) and protease inhibitors (Roche). The cells were
scraped, and the lysates were cleared by centrifugation at 14,000 g. The
lysates were normalized based on total protein content measured using the
Bradford assay. Equal amounts of proteins (3×1 mg) were subjected to
incubation with protein-A–Sepharose. After preclearing, the cell lysates
were incubated in the presence of antibodies or preimmune sera for 2 h at
4°C. After centrifugation (18,000 g for 1 min), the immune complexes were
washed extensively with ice-cold lysis buffer A and three times with ice-
cold lysis buffer B (10 mM Tris-HCl pH 7.5, 500 mM NaCl, 150 mM KCl,
12 mM 2-mercaptoethanol, 100 mM NaF, 0.5% NP-40, 0.01 μM sodium
vanadate and 2 mM EDTA) containing protease inhibitors.
Western blotting
Samples were loaded on polyacrylamide gels and run for 1.5 h. Proteins
were transferred onto nitrocellulose membranes, blocked in Odyssey
blocking buffer (LI-COR Biosciences), incubated with primary antibodies
overnight at 4°C. After 3 washes in PBS with Odyssey blocking buffer,
membranes were incubated with DyLight 680 anti-rabbit- and anti-mouse-
IgG or DyLight 800 anti-rabbit- and anti-mouse-IgG (Thermo Fisher
Scientific) for 1 h at room temperature, washed three times in PBS with
0.1% Tween 20 (BioRad). Membranes were scanned using a high sensitivity
Odyssey Infrared Imaging System (LI-COR Biosciences).
Identification of SHIP2 interactors by mass spectrometry
Immunoprecipitation was performed as described above, and the
precipitates were boiled for 5 min in SDS sample buffer and subjected to
SDS-PAGE (8% gels). The gel was stained with Coomassie Blue and
destained in 30% methanol in HPLC-grade water. The protein bands of
interacting proteins were excised and digested in situ with trypsin as
described previously (Elong Edimo et al., 2011). The resulting peptides
were desalted, concentrated with ZipTip C-18 (Millipore, Bedford, MA) and
analyzed using a ABI 4800 matrix assisted laser-desorption ionization
(MALDI)–time-of-flight (TOF)/TOF analyzer (Applied Biosystems, CA)
with α-cyano-4-hydroxycinnamic acid (5 mg/ml in 50% acetontrile) as the
matrix. The tandem mass spectrometry (MS/MS) results were submitted to
the Mascot 2.2.0 search engine with UniProtKB as the target database.
Lipid extraction and separation after [32P] labeling
2.5×106 N1 cells were cultured overnight in DMEM medium supplemented
with 5%FCS (Elong Edimo et al., 2011). Cells werewashed twice inmedium
without serum and incubated for 24 h in this medium. Cells were thenwashed
twice in medium without serum and without phosphate and labeled for 4 h in
medium containing [32P] but not phosphate. The phosphoinositides were
measured as described previously (Blero et al., 2005).
Immunofluorescence
Immunostaining in the presence of Triton X-100
Cells plated on coverslips were fixed in 4% paraformaldehyde for 20 min at
room temperature and incubated in 10 mM Tris-HCl pH 7.4, 0.15 M sodium
chloride (TBS) containing 0.1% (v/v) Triton X-100 (TBS-TX), 10% normal
horse serum (NHS) (Hormonologie Laboratoire, Marloie, Belgium) and 10%
normal goat serum (NGS) (Invitrogen) for 1 h at room temperature. The
coverslips were left overnight at 4°C in a humid chamber with the primary
antibodies diluted inTBS-TXcontaining 1%NHSand 1%NGS; theywere then
rinsed in TBS and then incubated in the dark for 1 h at room temperature in TBS
containing the secondary antibodies. Coverslips were then rinsed in TBS and
nuclei were stainedwith Hoechst 33342 dye 5 µM in Tris-HCl 0.05 M (pH 7.4)
for 2 min in the dark at room temperature. Primary antibodies raised in different
species and secondary antibodies coupled with different fluorochromes, were
combined to specifically label one marker in green (Alexa Fluor 488), the other
in red (Alexa Fluor 594). After three rinses in TBS, the coverslips weremounted
with Glycergel Mounting Medium anti-fade mounting medium.
Immunostaining in the presence of saponin for PI(4,5)P2 and PI4P staining
Cells plated on coverslips were fixed in formaldehyde 4% and 0.2%
glutaraldehyde for 15 min in a cold room. After three washes with PBS
containing 50 mM NH4Cl, the cells were incubated in buffer A (PIPES
20 mM pH 6.8, NaCl 137 mM, KCl 2.7 mM) containing 0.05% saponin,
5% NGS, 5% NHS and 50 mM NH4Cl for 45 min on ice to reduce
background staining. The coverslips were left overnight at 4°C in a humid
chamber with the primary antibodies diluted in buffer A containing 0.1%
saponin, 5% NGS and 5% NHS, then they were rinsed in buffer A and then
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incubated for 3 h on ice with biotin-conjugated goat anti-mouse-IgM
antibody diluted in buffer A containing 0.1% saponin, 5% NGS and 5%
NHS. They were then rinsed in buffer A and then incubated in the dark for
1 h on ice in buffer A containing 0.1% saponin, 5% NGS and 5% NHS
containing the secondary antibodies. Nuclei were stained with 5 µM
Hoechst 33342 dye in 0.05 M Tris-HCl pH 7.4 for 2 min in the dark at room
temperature. The specificity of PI(4,5)P2 staining was verified by the use of
neomycin as reported by Hammond et al. (2006).
Microscope image acquisition
The slides were examined under a Zeiss AxioImager Z1 microscope (Zeiss,
Oberkochen, Germany) equipped with a plan-Neofluar 40×0.75 NA
(numerical aperture) dry objective and band-pass filters (set numbers 38,
15 and 49 for green, red and blue fluorochromes, respectively). Images
(1388 by 1040 pixels) were acquired using a fixed exposure time with an
AxioCam MRm (Zeiss) as 3×12 bit RGB proprietary zvi files (Zeiss),
processed with AxioVision (4.6) software (Zeiss) and exported as 8-bit
uncompressed TIF files. A Zeiss LSM780 confocal system fitted on an
Observer Z1 inverted microscope equipped with alpha Plan-Apochromat
63×1.46 NA oil immersion objective (Zeiss, Iena, Germany) was used for
confocal imaging. High-resolution confocal microscopy ideal sampling was
calculated using a Nyquist calculator (Scientific Volume Imaging) for each
objective. Images were acquired sequentially for each fluorochrome in the
order infrared, red, green and blue, to avoid crosstalk. Resulting images were
deconvoluted using Huygens Professional software (4.2; Scientific Volume
Imaging). Z-planes containing structures of interest were projected into one
picture, merged and presented as an interpolation display using ZEN 2010 D
software (Carl Zeiss). For quantitative microscopy, images were taken under
the same settings for both groups. Contrast was adjusted identically for all
figures.
Fluorescence intensity quantification
Quantification was done using the AdvancedWeka Segmentation plugin for
ImageJ. Laser intensity and gain were set in the brightest sample below
saturation, and this was kept during acquisition for both groups. Confocal
images were deconvoluted and split into separate 16-bit TIF files. A binary
mask was created and used to extract the mean pixel intensity at the plasma
membrane per sample. Data were analyzed byMicrosoft Excel software and
plotted using Prism software (GraphPad).
Focal adhesion length measurement
pFAK Y397 as a focal adhesion marker and Hoechst 33342 was used for
counterstaining. Three nonoverlapping fields were acquired on LSM780
confocal system from three different experiments. Counting was done in
ImageJ (NIH). For length measurement, pFAKY397 signals were measured
using ZEN 2010 sofware.
Statistics
Data are mean±s.e.m.; they were analyzed by GraphPad Prism using two-
way ANOVA followed by Bonferroni post-test for the scratch test and focal
adhesion dynamics. For other data, we used a Student’s t-test (two-tailed)
followed by Mann–Whitney test. Statistical significance was defined as
P<0.05. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.
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K., Siegelin, M. D., Nonnenmacher, L. and Debatin, K.-M. (2014). A critical
evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. Mol.
Cell. Ther. 2, 32.
Wolfenson, H., Lavelin, I. and Geiger, B. (2013). Dynamic regulation of the
structure and functions of integrin adhesions. Dev. Cell 24, 447-458.
Xie, J., Vandenbroere, I. and Pirson, I. (2008). SHIP2 associates with intersectin
and recruits it to the plasma membrane in response to EGF. FEBS Lett. 582,
3011-3017.
Yu, J., Ryan, D. G., Getsios, S., Oliveira-Fernandes, M., Fatima, A. and Lavker,
R. M. (2008). MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2
levels in epithelia. Proc. Natl. Acad. Sci. USA 105, 19300-19305.
Yu, J., Peng, H., Ruan, Q., Fatima, A., Getsios, S. and Lavker, R. M. (2010).
MicroRNA-205 promotes keratinocyte migration via the lipid phosphatase SHIP2.
FASEB J. 24, 3950-3959.
Zaidel-Bar, R. and Geiger, B. (2010). The switchable integrin adhesome. J. Cell
Sci. 123, 1385-1388.
1114
RESEARCH ARTICLE Journal of Cell Science (2016) 129, 1101-1114 doi:10.1242/jcs.179663
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
